Terms: = Liver cancer AND ACSL3, PRO2194, 2181, ENSG00000123983, O95573, FACL3, ACS3
14 results:
1. Establishment of a prognostic signature based on fatty acid metabolism genes in HCC associated with hepatitis B.
Yan P; Luo Y; Huang Z; Mou T; Yang H; Peng D; Wu Z
BMC Gastroenterol; 2023 Nov; 23(1):390. PubMed ID: 37957550
[TBL] [Abstract] [Full Text] [Related]
2. Development of tryptophan metabolism patterns to predict prognosis and immunotherapeutic responses in hepatocellular carcinoma.
Long G; Wang D; Tang J; Tang W
Aging (Albany NY); 2023 Aug; 15(15):7593-7615. PubMed ID: 37540213
[TBL] [Abstract] [Full Text] [Related]
3. Pan-cancer analysis identifies LPCATs family as a prognostic biomarker and validation of LPCAT4/WNT/β-catenin/c-JUN/acsl3 in hepatocellular carcinoma.
Lu Y; Liang H; Li X; Chen H; Yang C
Aging (Albany NY); 2023 May; 15(11):4699-4713. PubMed ID: 37294538
[TBL] [Abstract] [Full Text] [Related]
4. Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in Hepatocellular Carcinoma.
Li C; Cui X; Li Y; Guo D; He S
Sci Rep; 2023 May; 13(1):8681. PubMed ID: 37248280
[TBL] [Abstract] [Full Text] [Related]
5. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
[TBL] [Abstract] [Full Text] [Related]
6. Immunohistochemical staining reveals differential expression of acsl3 and ACSL4 in hepatocellular carcinoma and hepatic gastrointestinal metastases.
Ndiaye H; Liu JY; Hall A; Minogue S; Morgan MY; Waugh MG
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32286604
[TBL] [Abstract] [Full Text] [Related]
7. Future Trends in Demand for liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC.
Shingina A; DeWitt PE; Dodge JL; Biggins SW; Gralla J; Sprague D; Bambha K
Transplantation; 2019 Jan; 103(1):140-148. PubMed ID: 30451739
[TBL] [Abstract] [Full Text] [Related]
8. The endogenous subcellular localisations of the long chain fatty acid-activating enzymes acsl3 and ACSL4 in sarcoma and breast cancer cells.
Radif Y; Ndiaye H; Kalantzi V; Jacobs R; Hall A; Minogue S; Waugh MG
Mol Cell Biochem; 2018 Nov; 448(1-2):275-286. PubMed ID: 29450800
[TBL] [Abstract] [Full Text] [Related]
9. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer.
Mutsaers A; Greenspoon J; Walker-Dilks C; Swaminath A
Radiat Oncol; 2017 Jun; 12(1):110. PubMed ID: 28662680
[TBL] [Abstract] [Full Text] [Related]
10. Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis.
Lee M; Baek SE; Moon J; Roh YH; Lim JS; Park MS; Kim MJ; Kim H
Oncotarget; 2016 Jun; 7(25):38513-38522. PubMed ID: 27229529
[TBL] [Abstract] [Full Text] [Related]
11. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
[TBL] [Abstract] [Full Text] [Related]
12. Long chain acyl-CoA synthetase-3 is a molecular target for peroxisome proliferator-activated receptor delta in HepG2 hepatoma cells.
Cao A; Li H; Zhou Y; Wu M; Liu J
J Biol Chem; 2010 May; 285(22):16664-74. PubMed ID: 20308079
[TBL] [Abstract] [Full Text] [Related]
13. Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma Huh7 cells.
Yao H; Ye J
J Biol Chem; 2008 Jan; 283(2):849-54. PubMed ID: 18003621
[TBL] [Abstract] [Full Text] [Related]
14. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.
Falkson G; Gelman R; Falkson CI; Glick J; Harris J
J Clin Oncol; 1991 Dec; 9(12):2153-61. PubMed ID: 1960558
[TBL] [Abstract] [Full Text] [Related]
